<DOC>
	<DOCNO>NCT02479087</DOCNO>
	<brief_summary>The purpose study assess role FVIII/VWF complex concentrate ( Emoclot ) successfully induce immune tolerance ( I.T.I . ) patient Haemophilia A inhibitor , include patient high risk failure .</brief_summary>
	<brief_title>Safety/Efficacy Study Assess Whether FVIII/VWF Concentrate Can Induce Immune Tolerance Haemophilia A Patients</brief_title>
	<detailed_description>The development factor VIII inhibitor occur approximately 30 40 % patient severe Haemophilia A . The main negative clinical cost consequence ineffectiveness replacement therapy patient high-titer antibody , short life great morbidity develop inhibitor . It known immunology regular frequent exposure antigen FVIII induce tolerance immune system patient inhibitor . This effect , call `` immune tolerance induction '' ( ITI ) usually achieve prolonged exposure patient FVIII , common way manage condition patient inhibitor well treatment bleed episode large amount hemostatic agent . In vitro retrospective clinical study suggest FVIII/VWF complex concentrate may less immunogenicity respect plasma-derived concentrate purify monoclonal antibody ( MABs ) , recombinant DNA factor VIII concentrate ( rFVIII ) , von Willebrand factor ( VWF ) absent . Immune tolerance induction ( ITI ) show effective 70 % Haemophiliacs inhibitor . Poor prognosis factor identify different registry : age â‰¥ 6 year , ITI start &gt; 1 year inhibitor development , inhibitor peak &gt; 200 BU , inhibitor titer &gt; 10 BU start ITI previously fail ITI . The result clinical study suggest complex concentrate VWF/FVIII effective ITI , even patient high risk failure . To explain finding , role VWF ( i.e . prolonged antigen exposure ) hypothesize .</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>1 . Subjects ( his/her parent/legal representative ) , must give write informed consent . 2 . Male child : age &lt; 12 year . 3 . Severe moderate Haemophilia A ( FVIII &lt; 2 % ) . 4 . High responder ( clinical history inhibitor peak &gt; 5BU ) lowresponders ( clinical history inhibitor peak &lt; 5 BU ) potential bleeding , assess responsible physician treat high FVIII dos . 5 . Any level inhibitor study enrollment . 6 . Willingness ability participate study . 7 . No experimental treatment ( involve FVIII concentrate ) . 1 . Any clinically relevant abnormality , hematological , biochemical urinary routine examination , condition treatment investigator 's opinion , make patient eligible study . 2 . Intolerance active substance excipients FVIII / VWF concentrate . 3 . Concomitant systemic treatment immunosuppressive drug .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>von Willebrand Factor</keyword>
	<keyword>Factor VIII</keyword>
	<keyword>Hemorrhage</keyword>
	<keyword>Immune Tolerance</keyword>
	<keyword>Hemophilia A</keyword>
</DOC>